miR-34b/c启动子区基因多态性与肿瘤易感性的Meta分析

国际肿瘤学杂志››2015,Vol. 42››Issue (1): 27-31.doi:10.3760/cma.j.issn.1673-422X.2015.01.007

miR-34b/c启动子区基因多态性与肿瘤易感性的Meta分析

曾慧, 曾拓, 龙行华

430071武汉大学中南医院检验科（曾慧、龙行华）；贵州师范大学生命科学院（曾拓）

收稿日期:2014-06-27修回日期:2014-09-29出版日期:2015-01-08发布日期:2015-01-07
通讯作者:龙行华 E-mail:xlong888@yahoo.com
基金资助:

国家自然科学基金（30873044、81272372）；教育部留学回国人员科研启动基金(教外司留［2011］1139号)

Roles of polymorphism in promoter region of miR-34b/c in cancer: a Meta analysis

Zeng Hui, Zeng Tuo, Long Xinghua

Department of Clinical Laboratory, Zhongnan Hospital of Wuhan University, Wuhan 430071, China

Received:2014-06-27Revised:2014-09-29Online:2015-01-08Published:2015-01-07
Contact:Long Xinghua E-mail:xlong888@yahoo.com

摘要/Abstract

摘要：目的探讨微小RNA-34b/c(miR-34b/c)启动子区基因多态性与肿瘤易感性的关系。方法全面检索PubMed、EMBASE、万方、维普和中国知网等中英文数据库，纳入符合标准的病例对照研究，运用RevMan 5.1软件对数据进行合并分析。结果总共纳入9篇文献10项病例对照研究，Meta分析结果显示miR34b/c启动子区基因多态性与肿瘤在C vs T、CC vs TT、CC+CT vs TT以及CC vs CT+TT这4种模型分析中易感性无明显相关性，但在CT vs TT模型分析中，结果显示出显著的相关性（Z=2.33,P=0.02）。根据肿瘤的类型进行亚组分析发现，在肝细胞肝癌，C vs T(Z=2.10,P=0.04)、CT vs TT(Z=2.40,P=0.02)以及CC+CT vs TT（Z=2.45,P=0.01）模型中相关性均具有统计学意义。C等位基因明显增加了肝癌的易感性（OR=1.11，Z=2.10，P=0.04），但在结直肠癌的研究中发现，在CC vs TT和CC vs CT+TT模型中，CC基因型能显著降低结直肠癌的易感性，OR值分别为0.66（Z=2.43,P=0.02）、0.67（Z=2.40,P=0.02）。结论miR34b/c启动子区基因多态性rs4938723 T＞C与肝癌和结直肠癌的易感性存在一定的相关性。

关键词:肿瘤,多态现象,遗传,Meta分析,miR-34b/c

Abstract:Objective To investigate the association between the genetic variant in the promoter region of miR34b/c and cancer risk. MethodsDatabases such as PubMed、EMBase、Wanfang、VIP、CNKI and so on were searched comprehensively. Based on the including and excluding criteria, literatures that were eligible were screened and data were retrieved. Meta analysis was performed by RevMan 5.1 software. ResultsThrough searching and manually searching relevant references, a total of 9 articles with 10 independent studies were included. No significant associations were detected in C vs T, CC vs TT, CC+CT vs TT and CC vs CT+TT comparison models. However, in the CT vs TT comparison model, the result showed a significant association (Z=2.33, P=0.02). Meanwhile, subgroup analysis of hepatocellular carcinoma and colorectal cancer both showed significant associations with the polymorphism, with C vs T (OR=1.11, Z=2.10, P=0.04), CT vs TT (Z=2.40, P=0.02), CC+CT vs TT (Z=2.45, P=0.01) and CC vs TT (OR=0.66, Z=2.43, P=0.02）, CC vs CT+TT (OR=0.67, Z=2.40, P=0.02) respectively. The C allele increased significantly the susceptibility of hepatocellular carcinoma, and the CC genotype reduced significantly the susceptibility of colorectal cancer. ConclusionThe genetic variant in the promoter region of miR34b/c rs4938723 T>C is significantly associated with the susceptibility of hepatocellular carcinoma and colorectal cancer.

Key words:Neoplasms,Polymorphism, genetic,Meta-analysis,miR-34b/c

曾慧, 曾拓, 龙行华. miR-34b/c启动子区基因多态性与肿瘤易感性的Meta分析[J]. 国际肿瘤学杂志, 2015, 42(1): 27-31.

Zeng Hui, Zeng Tuo, Long Xinghua. Roles of polymorphism in promoter region of miR-34b/c in cancer: a Meta analysis[J]. Journal of International Oncology, 2015, 42(1): 27-31.

参考文献

［1］ He L, He X, Lim LP, et al. A microRNA component of the p53 tumour suppressor network［J］. Nature, 2007, 447(7148): 1130-1134. ［2］ Wang JX, Jiao JQ, Li Q, et al. MiR499 regulates mitochondrial dynamics by targeting calcineurin and dynaminrelated protein1［J］. Nat Med, 2011, 17(1): 71-78. ［3］ Hu Z, Chen J, Tian T, et al. Genetic variants of miRNA sequences and nonsmall cell lung cancer survival［J］. J Clin Invest, 2008, 118(7): 2600-2608. ［4］ Stang A. Critical evaluation of the NewcastleOttawa scale for the assessment of the quality of nonrandomized studies in metaanalyses［J］. Eur J Epidemiol, 2010, 25(9): 603-605. ［5］ Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in metaanalyses［J］. BMJ, 2003, 327(7414): 557-560. ［6］ DerSimonian R, Kacker R. Randomeffects model for metaanalysis of clinical trials: an update［J］. Contemp Clin Trials, 2007, 28(2): 105-114. ［7］ Higgins JP, Thompson SG. Quantifying heterogeneity in a metaanalysis［J］. Stat Med, 2002, 21(11): 1539-1558. ［8］ Bensen JT, Tse CK, Nyante SJ, et al. Association of germline microRNA SNPs in premiRNA flanking region and breast cancer risk and survival: the carolina breast cancer study［J］. Cancer Causes Control, 2013, 24(6): 1099-1109. ［9］ Gao LB, Li LJ, Pan XM, et al. A genetic variant in the promoter region of miR34b/c is associated with a reduced risk of colorectal cancer［J］. Biol Chem, 2013, 394(3): 415-420. ［10］ Han Y, Pu R, Han X, et al. Associations of primiR34b/c and premiR196a2 polymorphisms and their multiplicative interactions with hepatitis B virus mutations with hepatocellular carcinoma risk［J］. PLoS One, 2013, 8(3): e58564. ［11］ Li L, Wu J, Sima X, et al. Interactions of miR34b/c and TP53 polymorphisms on the risk of nasopharyngeal carcinoma［J］. Tumour Biol, 2013, 34(3): 1919-1923. ［12］ Oh J, Kim JW, Lee BE, et al. Polymorphisms of the primiR34b/c promoter and TP53 codon 72 are associated with risk of colorectal cancer［J］. Oncol Rep, 2014, 31(2): 995-1002. ［13］ Son MS, Jang MJ, Jeon YJ, et al. Promoter polymorphisms of primiR34b/c are associated with hepatocellular carcinoma［J］. Gene, 2013, 524(2): 156-160. ［14］ Xu Y, Liu L, Liu J, et al. A potentially functional polymorphism in the promoter region of miR34b/c is associated with all increased risk for primary hepatocellular carcinoma［J］. Int J Cancer, 2011, 128(2): 412-417. ［15］ Yin J, Wang X, Zheng L, et al. HsamiR34b/c rs4938723 T>C and hsamiR423 rs6505162 C>A polymorphisms are associated with the risk of esophageal cancer in a Chinese population［J］. PLoS One, 2013, 8(11): e80570. ［16］ Zhang S, Qian J, Cao Q, et al. A potentially functional polymorphism in the promoter region of miR34b/c is associated with renal cell cancer risk in a Chinese population［J］. Mutagenesis, 2014, 29(2): 149-154. ［17］ Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin4 encodes small RNAs with antisense complementarity to lin14［J］. Cell, 1993, 75(5): 843-854. ［18］ Lee Y, Ahn C, Han J, et al. The nuclear RNase Ⅲ Drosha initiates microRNA processing［J］. Nature, 2003, 425(6956): 415-419. ［19］ Kong W, Zhao JJ, He L, et al. Strategies for profiling microRNA expression［J］. J Cell Physiol, 2009, 218(1): 22-25. ［20］ Hutvágner G, McLachlan J, Pasquinelli AE, et al. A cellular function for the RNAinterference enzyme Dicer in the maturation of the let-7 small temporal RNA ［J］. Science, 2001, 293(5531): 834-838. ［21］ Dahiya N, ShermanBaust CA, Wang TL, et al. MicroRNA expression and identification of putative miRNA targets in ovatian cancer［J］. PLoS One, 2008, 3(6): e2436. ［22］ Kogo R, Mimori K, Tanaka F, et al. Clinical significance of miR146a in gastric cancer cases［J］. Clin Cancer Res, 2011, 17(13): 4277-4284. ［23］ Yu F, Yao H, Zhu P, et al. Let7 regulates self renewal and tumorigenicity of breast cancer cells［J］. Cell, 2007, 131(6): 1109-1123. ［24］ Kumar MS, Lu J, Mercer KL, et al. Impaired microRNA processing enhances cellular transformation and tumorigenesis［J］. Nat Genet, 2007, 39(5): 673-677. ［25］ Guo Z, Wu C, Wang X, et al. A polymorphism at the miR502 binding site in the 3′untranslated region of the histone methyltransferase SET8 is associated with hepatocellular carcinoma outcome［J］. Int J Cancer, 2012, 131(6):1318-1322. ［26］ Liu AM, Zhang C, Burchard J, et al. Global regulation on microRNA in hepatitis B virusassociated hepatocellular carcinoma［J］. OMICS, 2011, 15(3): 187-191. ［27］郭哲, 向邦德. 微小RNA在肝细胞癌及肝癌干细胞中的作用［J］. 国际肿瘤学杂志, 2011, 38(9): 680-683. ［28］张灵敏, 王亚旭. 微小RNA与结直肠癌［J］. 国际肿瘤学杂志, 2014, 41(4)：290-293.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲.血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊.局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华.Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青.血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺.PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云.新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚.EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵.抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六.基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六.肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东.ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅.基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳.炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝.癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志.宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.